title: Neck recurrence and mortality in esthesioneuroblastoma: Implications for management of the N0 neck.
abstract: To review the literature on neck recurrence in esthesioneuroblastoma.
  
  
  
  PubMed database.
  
  
  
  A PubMed database search was performed using keywords "esthesioneuroblastoma," "olfactory neuroblastoma," and "esthesioneuroblastoma neck metastasis." Articles written in English with greater than 10 subjects that had data regarding the association of neck recurrence and mortality and/or the association of neck recurrence with Kadish stage were included for analysis.
  
  
  
  Thirteen studies met inclusion criteria with information regarding the association of neck recurrence and mortality, and 15 studies had data associating neck recurrence and Kadish stage. The neck recurrence rate was 14.1% in studies analyzing mortality. Among those patients who developed regional metastases, mortality was 60%. Of patients without regional recurrence, the mortality rate from disease was 26% (P < 0.0001) and overall mortality was 32% (P < 0.0001). The rate of neck recurrence within each Kadish stage was 0%, 11%, 21%, and 18% for Kadish stages A, B, C, and D, respectively. The trend toward an increased incidence of neck recurrence from stage A to stage D is statistically significant, with P value 0.003.
  
  
  
  The rate of neck recurrence in esthesioneuroblastoma is close to 15%. There is a strong association of recurrence with Kadish stage B and C. Mortality from disease in patients with recurrence in cervical lymph nodes is significant when compared to those who never develop neck disease. Prospective studies are needed to evaluate a potential role for elective neck dissection versus elective neck radiation for patients with esthesioneuroblastoma.
  
  
  
  N/A. Laryngoscope, 126:1373-1379, 2016.
authors.affiliation: Department of Otolaryngology, UConn Health, Farmington, Connecticut, U.S.A.
authors.forename: James G
authors.initials: JG
authors.lastname: Naples
authors.affiliation: Department of Otolaryngology, UConn Health, Farmington, Connecticut, U.S.A.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Spiro
authors.affiliation: Department of Otolaryngology, Connecticut Sinus Institute, UConn Health, Farmington, Connecticut, U.S.A.
authors.forename: Belachew
authors.initials: B
authors.lastname: Tessema
authors.affiliation: Department of Otolaryngology, Hartford Hospital Head and Neck Cancer Center, UConn Health, Farmington, Connecticut, U.S.A.
authors.forename: Clinton
authors.initials: C
authors.lastname: Kuwada
authors.affiliation: Biostatistics Center, Community Medicine and Health Care, CT Institute for Clinical & Translational, Science, UConn Health, Farmington, Connecticut, U.S.A.
authors.forename: Chia-Ling
authors.initials: CL
authors.lastname: Kuo
authors.affiliation: Department of Otolaryngology, Connecticut Sinus Institute, UConn Health, Farmington, Connecticut, U.S.A.
authors.forename: Seth M
authors.initials: SM
authors.lastname: Brown
mesh_terms: D018304:Esthesioneuroblastoma, Olfactory / Q000401:mortality / Q000473:pathology*; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D009296:Nasal Cavity / Q000473:pathology*; D009333:Neck / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology*; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology*
keywords: Esthesioneuroblastoma; Kadish; elective neck treatment; neck recurrence; olfactory neuroblastoma